Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808103 | 0.94 | NPSR1 (0.39) | SLC22A1KDM4ENPSR1OPRM1NPC1 | |
| SCHEMBL4813933 | 0.90 | NPC1 (0.41) | NPSR1OPRK1NPC1RAB9AMAPT | |
| SCHEMBL4810099 | 0.90 | ADRB2 (0.41) | SLC22A1NPSR1NPC1RAB9AMAPT | |
| SCHEMBL4815215 | 0.88 | SLC22A1 (0.43) | SLC22A1OPRM1OPRD1OPRK1NPC1 | |
| SCHEMBL4813759 | 0.88 | SLC22A1 (0.46) | SLC22A1NPSR1OPRM1OPRD1OPRK1 | |
| SCHEMBL4815386 | 0.84 | ADRB2 (0.41) | NPSR1NPC1RAB9AMAPT | |
| SCHEMBL4815646 | 0.84 | SMN1; SMN2 (0.41) | NPSR1OPRK1NPC1RAB9AMAPT | |
| SCHEMBL4810401 | 0.83 | PTPN2 (0.44) | KDM4ENPSR1NPC1RAB9AMAPT | |
| SCHEMBL4815535 | 0.82 | OPRM1 (0.43) | SLC22A1NPSR1OPRM1RAB9AMAPT | |
| SCHEMBL4813929 | 0.82 | SLC22A1 (0.50) | SLC22A1OPRM1OPRD1OPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | SLC22A1 3001/4885KDM4E 2912/4885NPSR1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.